Gain Therapeutics has shared early safety and tolerability findings, the primary endpoint, and observations from key exploratory endpoints from the Phase Ib clinical study of GT-02287 in people with Parkinson’s disease (PD) with or without a GBA1 mutation. 

The findings were presented in a poster at the International Congress of Parkinson’s Disease and Movement Disorders. 

“We are pleased to be able to present encouraging early takeaways from our Phase Ib study,” said Gene Mack, President and Chief Executive Officer of Gain Therapeutics. “The stability and trending improvements we have observed in MDS-UPDRS scores was not something we were expecting to see with 90 days of dosing. We look forward to further contextualising our observations in an upcoming webinar.” 

GT-02287 was generally well tolerated, with no treatment-emergent serious adverse events observed. 

Of the 21 participants, two are treatment-naïve, two are on deep brain stimulation, and 18 are on levodopa and/or dopamine agonists or other PD drugs. 

Mean MDS-UPDRS scores at baseline were 5.8, 7.4, and 24.7 for Parts I, II, and III, respectively. Importantly, several participants experienced an improvement in their UPDRS Part II and III scores after 90 days of dosing with GT-02287 while mean Part I scores remained unchanged.  

The mean improvement in Parts II and III by Day 90, which was not observed by Day 30, suggests that GT-02287 has a disease-slowing effect, consistent with the preclinical models in vivo and the proposed mechanism of action of GT-02287, supporting continued development. 

The plasma pharmacokinetics (PK) profile was consistent across all 14 participants sampled, was within the projected therapeutics range, and comparable to exposures observed in healthy volunteers in the Phase I study. 

How does GT-02287 work?

GT-02287 is an allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors.  

In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced ER stress, lysosomal and mitochondrial pathology, aggregated α-synuclein, neuroinflammation and neuronal death, as well as plasma neurofilament light chain (NfL) levels, a biomarker of neurodegeneration.  

In rodent models of both GBA1-PD and idiopathic PD, GT-02287 was shown to rescue deficits in motor function and gait and prevent the development of deficits in complex behaviours such as nesting. 

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow or stop the progression of Parkinson’s disease.

Diana Turner, Deputy Editor, DDW